# A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.

> **NCT05191563** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP1904-1
- **DRUG:** RLD2006
- **DRUG:** RLD2001-2

## Key facts

- **NCT ID:** NCT05191563
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-31
- **Primary completion:** 2021-09-12
- **Final completion:** 2021-09-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05191563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05191563, "A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05191563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*